0001209191-23-056180.txt : 20231120
0001209191-23-056180.hdr.sgml : 20231120
20231120205437
ACCESSION NUMBER: 0001209191-23-056180
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231116
FILED AS OF DATE: 20231120
DATE AS OF CHANGE: 20231120
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lee Gary K.
CENTRAL INDEX KEY: 0001907345
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40502
FILM NUMBER: 231424247
MAIL ADDRESS:
STREET 1: C/O LYELL IMMUNOPHARMA, INC.
STREET 2: 201 HASKINS WAY
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Lyell Immunopharma, Inc.
CENTRAL INDEX KEY: 0001806952
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 833006753
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 201 HASKINS WAY
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650 695-0677
MAIL ADDRESS:
STREET 1: 201 HASKINS WAY
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-11-16
0
0001806952
Lyell Immunopharma, Inc.
LYEL
0001907345
Lee Gary K.
C/O LYELL IMMUNOPHARMA, INC.
201 HASKINS WAY
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
Chief Scientific Officer
0
Common Stock
12700
D
Stock Option (right to buy)
1.87
2023-11-16
4
A
0
800000
A
2032-02-10
Common Stock
800000
800000
D
Stock Option (right to buy)
6.04
2023-11-16
4
D
0
800000
D
2032-02-10
Common Stock
800000
0
D
Includes 4,702 shares acquired on November 18, 2022, 6,205 shares acquired on May 18, 2023 and 1,793 shares acquired on November 17, 2023 under the Issuer's 2021 Employee Stock Purchase Plan.
350,000 shares were vested as of November 16, 2023 and the remaining unvested shares will vest in equal monthly installments over the following thirty-nine months based on the original vesting commencement date.
The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on November 16, 2023 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.37 per share held by all continuing employees of the Issuer as of the Repricing Date.
Pursuant to the Option Repricing, the exercise price of the repriced options, including the Option, has been amended to reduce the exercise price to $1.87 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. In addition, the vesting schedule for the unvested shares underlying repriced options held by executive officers, including the reporting person, was extended for an additional year. There is no change to the expiration dates of or number of shares underlying the repriced options.
1/4 of the option shares vested on January 31, 2023, with the remaining option shares vesting in equal monthly installments over the following thirty-six months.
/s/ Hector Casab, as Attorney-in-Fact
2023-11-20